MHRA Approves Catumaxomab for Malignant Ascites Treatment

• The MHRA has approved catumaxomab (Korjuny) for treating malignant ascites in adult cancer patients when standard therapies are no longer feasible.
• This monoclonal antibody works by targeting EpCAM-positive cancer cells and activating the immune system to destroy them.
• A clinical study showed catumaxomab extended the time between abdominal fluid drainage procedures to approximately 46 days, compared to 11 days with paracentesis alone.
• The approval was granted to Atnahs Pharma UK Limited on October 2, utilizing the International Recognition Procedure.
• The MHRA will continue to closely monitor the drug's safety and effectiveness, encouraging reporting of side effects via the Yellow Card scheme.

This approval provides an additional treatment option that can help extend the time patients live without needing another procedure to drain fluid from their abdomen.

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for catumaxomab, marketed as Korjuny, to address malignant ascites in adult patients. This new therapeutic option is specifically indicated for individuals whose standard cancer treatments are no longer viable. Malignant ascites is a severe condition characterized by the accumulation of fluid containing cancer cells within the abdominal cavity, often necessitating frequent drainage procedures.

Catumaxomab offers a crucial intervention by extending the duration between these required drainage procedures. The drug functions as a monoclonal antibody, a specialized protein designed to target specific cellular components. It specifically recognizes the epithelial cell adhesion molecule (EpCAM), a protein found on the surface of certain cancer cells, including those present in ascitic fluid. By binding to EpCAM, catumaxomab activates the body's immune system cells, prompting them to destroy these cancerous cells.

Clinical evidence supporting this approval stems from a significant study involving 258 patients suffering from malignant ascites and EpCAM-positive cancer, for whom chemotherapy was either unsuitable or no longer an option. Patients who received catumaxomab following paracentesis—the procedure to drain abdominal fluid—experienced approximately 46 days before requiring further drainage. This contrasts sharply with patients treated solely with paracentesis, who typically needed additional drainage after just 11 days.

The administration of catumaxomab requires the oversight of a physician experienced in oncology. It is delivered directly into the abdominal cavity via a catheter, through a regimen of four infusions, with the dosage progressively increasing with each subsequent infusion. Patients should be aware of potential common side effects, which include nausea, vomiting, diarrhoea, abdominal pain, fever, chills, fatigue, and cytokine release syndrome, an inflammatory response triggered by immune system activation.

This significant marketing authorization for catumaxomab was granted to Atnahs Pharma UK Limited on October 2. Notably, the approval was secured through the International Recognition Procedure, a pathway that streamlines the authorization process for medicines already approved by trusted regulatory bodies in other jurisdictions. This mechanism underscores a strategic approach by the UK's Medicines and Healthcare products Regulatory Agency to facilitate access to innovative treatments.

The MHRA, operating as an executive agency under the Department of Health and Social Care, holds the critical responsibility for regulating all medicines and medical devices within the United Kingdom. Its mandate ensures that pharmaceutical products are both effective and acceptably safe for public use. The agency's decisions are consistently grounded in robust, fact-based judgments, ensuring that the potential benefits of any approved medicine demonstrably outweigh its associated risks.

Further detailed information regarding catumaxomab, including its Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL), is slated for publication on the MHRA Products website within seven days of the approval date. This ensures transparency and provides comprehensive guidance for both healthcare professionals and patients regarding the medicine's proper use and safety profile.

As with all newly licensed medicines, the MHRA maintains a vigilant stance on the ongoing safety and effectiveness of catumaxomab. This commitment to post-market surveillance is a cornerstone of UK pharmaceutical regulation, ensuring that any emerging safety concerns are promptly identified and addressed. Healthcare professionals and patients alike are strongly encouraged to report any suspected side effects through the MHRA’s established Yellow Card scheme, a vital component of the agency's pharmacovigilance efforts.

Julian Beach, the MHRA's Interim Executive Director of Healthcare Quality and Access, emphasized the profound impact of malignant ascites on individuals battling cancer, particularly when conventional treatment options become limited. He highlighted that this approval introduces an additional therapeutic avenue designed to prolong the period patients can live without the need for further fluid drainage from their abdomen. This focus on improving quality of life and reducing invasive procedures is a key benefit of the new treatment.

The agency's continuous monitoring, including the active participation in the Yellow Card scheme, reinforces its dedication to patient safety. This systematic approach ensures that while innovative treatments like Korjuny are made available, their real-world performance and safety profiles are meticulously tracked, allowing for informed regulatory adjustments if necessary.

Lawyers advising pharmaceutical companies should note this MHRA approval of catumaxomab, particularly the successful use of the International Recognition Procedure, as a precedent for future marketing authorisation applications in the UK. Compliance officers should be aware of ongoing pharmacovigilance requirements, including the Yellow Card scheme, for newly approved medicines.

Source: Original reporting via GOV.UK